Activated endothelium and vascular inflammation interfaces

The activated endothelium and vascular inflammation interface refers to the phenotypic transformation of the vascular lining in response to inflammatory stimuli, such as cytokines (TNF-alpha, IL-1) or mechanical stress. This "activated" state is characterized by the upregulated expression of cell adhesion molecules—including E-selectin, ICAM-1, and VCAM-1—which facilitate the rolling, adhesion, and transmigration of leukocytes into underlying tissues (Ley et al., 2007, Nature Reviews Immunology). This interface is a hallmark of chronic inflammatory conditions like atherosclerosis and acute states like sepsis, where excessive leukocyte recruitment leads to tissue damage (Pober & Sessa, 2007, Nature Reviews Immunology). Therapeutic strategies targeting this interface aim to modulate endothelial signaling or block specific adhesion pathways to dampen the inflammatory response. Drugs such as statins and monoclonal antibodies are used to inhibit these interactions and reduce vascular damage (Gimbrone & García-Cardeña, 2016, Circulation Research). By inhibiting these interactions, clinicians can reduce tissue damage and improve outcomes in cardiovascular and autoimmune diseases. Monitoring soluble forms of these adhesion molecules, such as sICAM-1, serves as a biomarker for disease activity and treatment efficacy (Blann, 1993, Journal of Hypertension).

Other names

Endothelial activationVascular inflammatory interfaceLeukocyte-endothelial interactionEndothelial dysfunction

Inhibition of pro-inflammatory cytokine signaling, downregulation of cell adhesion molecule expression (ICAM-1, VCAM-1, Selectins), and blockade of leukocyte-endothelial binding interactions.